Tofacitnib for the Treatment of Alopecia Areata and Variants

Completed · Phase 2

Conditions studied: Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)

In brief

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Key facts

Study ID
NCT02197455
Run by
Yale University
People needed
30
Starts
2014-07-01
Expected to finish
2015-07-01
Last updated by the study team
2017-04-04

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.